Surety Medicine 
Soldier uses RSDL training packet for spot decontamination.  US Army photo 

FEBRUARY 2013 SURETY MEDICINE TELECONFERENCE:

Updates on Patient Decontamination and RSDL

Please join us Wednesday, 20 February 2013 at 1 p.m. Eastern Time (US) as a physician from the U.S. Army Medical Research Institute of Chemical Defense at Aberdeen Proving Ground, Maryland presents updated information on patient decontamination procedures and the use of reactive skin decontamination lotion (RSDL).  RSDL is specified as the "preferred alternative" for patient spot decontamination in the recently released Interim Guidance on Occupational Health Practices for the Evaluation and Control of Occupational Exposures to Nerve Agents GA, GB, GD, GF, and VX and Mustard Agents H, HD, and HT (16 November 2012). 

To receive access information for attending the presentation by dial-in audio or at your desk via Defense Connect Online, send an email request to suretymedicine@amedd.army.mil

 Join us for future Surety Medicine teleconferences, including:

SURETY MEDICINE TELECONFERENCE SCHEDULE FOR FY13
All conferences begin at 1300 hr / 1 p.m. Eastern Time (US)

Presentation Title

Date

Topic Objectives

Updates on Patient Decontamination Doctrine and the Use of Reactive Skin Decontamination Lotion (RSDL)

20 February
2013

Given a patient with potential chemical agent exposure in a garrison, laboratory or field environment, describe the appropriate techniques for spot decontamination, definitive decontamination and/or quadrant monitoring.

Updates in the Diagnosis and Treatment of Nerve Agent and Vesicant Agent Exposures

20 March
2013

Given a worker with a potential stockpile exposure to nerve agents or vesicants, outline the latest clinical approaches for treating these types of chemical agent casualties. 

Case Studies in PRP Substance Abuse and Dependency Evaluations

17 April
2013

Given the CMA responsibilities defined in ARs 50-1, 50-5, 50-6, and 600-85, outline the clinical approach to evaluating PRP members or candidates for substance abuse and dependency.

Vision Conservation and Readiness Program: The CMA Perspective

15 May
2013

Given the ocular hazards and special vision requirements associated with chemical, biological and nuclear surety programs, discuss the potential PRP reliability or suitability issues identified during vision screening or comprehensive vision examinations described in DA PAM 40-506

Licensed Immunization Program

19 June
2013

Given a list of biological select agents and toxins (BSATs) to which employees working in BSL-3 bio-containment might be exposed, identify those licensed vaccines which might be appropriate to administer, and describe the process of medical screening, clearance, documentation and follow-up, with contingencies for treating adverse vaccine reactions. 

Hearing Conservation, Audiometric Testing, and Hearing in Noise Testing in Surety Programs

17 July
2013

Given a worker with significant threshold shifts, discuss the approach to evaluating hearing loss, and the ability to communicate in a noisy environment, IAW DA PAM 40-501 AR 190-56, Appendix C, and the Guidelines from the USACHPPM (now USAPHC), 7 November 2002, Evaluation of Occupational Hearing Loss.

Case Studies in Chemical, Biological and PRP Surety Management

21 August
2013

Given the disqualifying factors contained in AR 50-1 and AR 50-6, evaluate a worker’s medical suitability for enrollment and retention in the biological personnel reliability program and/or chemical personnel reliability program.

BSAT Potential Exposure Evaluations

18 Sept
2013

BSAT Potential Exposure Evaluations – Given a patient potentially exposed to BSATs in a BPRP setting, outline the specific steps to take IAW MEDCOM 40-55 in documenting the circumstances of exposure, evaluating the risk of exposure/risk of disease, and providing the appropriate post-exposure surveillance and follow-up care.

Related programs and contacts